Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) stands out as a candidate for multi-decade portfolios because it pairs a AAA credit rating with 64 consecutive years of dividend increases, a combination almost no other public company in the world can match.
For a retirement-focused investor who is tired of watching a portfolio bounce on every headline, this is the rare name often considered for a permanent portfolio slot. The case rests on three pillars: durability, income, and the ability to keep paying you through every kind of market.
Pillar 1: A Business Built to Outlast Cycles
Healthcare demand does not move with the business cycle. People do not choose when they get sick, which means demand for life-saving drugs and medical devices stays constant regardless of what Wall Street is doing on any given day. After the Kenvue spinoff, Johnson & Johnson is a pure-play Innovative Medicine and MedTech company, with revenue spread across six priority areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision.
The numbers behind that durability are unusual. Q1 2026 revenue came in at $24.062 billion, up 9.9% year over year, with adjusted EPS of $2.70 beating consensus for the fourth consecutive quarter. Operating margin sits at 27.4% and return on equity at 26.4%. The stock’s beta of 0.263 tells you exactly how it behaves when the market panics: barely.
Pillar 2: Income That Compounds Without Drama
In April, the board approved a 3.1% dividend increase to $1.34 per share, extending the streak to 64 consecutive years. The current annualized dividend of $5.20 works out to a 2.33% yield, and the company generated $19.7 billion in free cash flow in full-year 2025 to back it.
The growth pattern matters more than the headline yield. Quarterly payouts have risen from $1.01 in Q1 2021 to $1.34 in Q2 2026, with no cuts through the 2008 financial crisis, the 2020 pandemic, or any recession in between. That is what reliable compounding looks like in practice.
Pillar 3: Surviving What Breaks Other Stocks
Cycle survival comes from balance sheet strength and pipeline depth. Johnson & Johnson is one of only two U.S. public companies with a AAA credit rating, higher than the U.S. government itself. The pipeline keeps producing: DARZALEX grew 22.5%, CARVYKTI grew 62.1%, and TREMFYA grew 68.3% in Q1 2026. Management raised 2026 guidance to $100.3B-$101.3B in revenue with a stated path to double-digit growth by end of decade.
The Scenario Where It Lags
JNJ will underperform during risk-on rallies when speculative growth names dominate. The current biosimilar erosion of STELARA, which fell 59.7% in Q1 2026 to $656 million, is a real headwind. That does not change the forever thesis because TREMFYA, DARZALEX, and CARVYKTI are already absorbing the share. Patent cliffs are a recurring event for Johnson & Johnson, and the company has survived every previous one by replacing the lost revenue with new approvals. CEO Joaquin Duato called 2025 a “catapult year” for that exact reason.
For long-term holders, the framework is straightforward: collect the dividends, reinvest them, and let compounding do the work.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks